EKF Diagnostics (LON:EKF) Insider Julian Baines Buys 85,000 Shares

EKF Diagnostics Holdings plc (LON:EKF) insider Julian Baines acquired 85,000 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was purchased at an average cost of GBX 23 per share, with a total value of £19,550.

EKF Diagnostics Price Performance

EKF opened at GBX 25 on Tuesday. The stock’s 50-day moving average price is GBX 25.89 and its 200 day moving average price is GBX 27.29. EKF Diagnostics Holdings plc has a 12-month low of GBX 18.40 and a 12-month high of GBX 32. The firm has a market cap of £108.85 million, a price-to-earnings ratio of 18.52 and a beta of 0.57. The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34.

EKF Diagnostics (LON:EKF) last released its earnings results on Tuesday, September 16th. The company reported GBX 0.43 earnings per share for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. As a group, sell-side analysts expect that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current year.

EKF Diagnostics Company Profile

EKF is an AIM-listed global diagnostics business focussed on:

● Point-of-Care analysers in the key areas of Hematology and Diabetes

● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.